Posts

Showing posts with the label Antibody Drug Conjugates Contract Manufacturing Market 2028

Antibody Drug Conjugates Contract Manufacturing Market Projected To Reach USD 18.4 Billion By 2028

Image
  San Francisco, 27 Jan 2022:   The Report  Antibody Drug Conjugates Contract Manufacturing Market  Size, Share & Trends Analysis Report By Condition (Myeloma, Lymphoma, Breast Cancer), By Linker (Cleavable Linker, Non-cleavable Linker), By Region, And Segment Forecasts, 2021 - 2028 The global antibody drug conjugates contract manufacturing market size is anticipated to reach USD 18.4 billion by 2028, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 12.3% from 2021 to 2028. The factors driving market expansion is complex nature of Antibody Drug Conjugates (ADCs), increasing demand for manufacturing capacity as well as increasing number of research on antibody therapies. Around 70.0% of ADC projects are outsourced to contract development and manufacturing organisations. As ADCs are complex molecules, they require clean room biologic and high containment cytotoxic facilities for safe handling. Hence, there are real opportunities for

Antibody Drug Conjugates Contract Manufacturing Market Projected To Reach USD 18.4 Billion By 2028

Image
  San Francisco, 10 Nov 2021:   The Report  Antibody Drug Conjugates Contract Manufacturing Market  Size, Share & Trends Analysis Report By Condition (Myeloma, Lymphoma, Breast Cancer), By Linker (Cleavable Linker, Non-cleavable Linker), By Region, And Segment Forecasts, 2021 - 2028 The global antibody drug conjugates contract manufacturing market size is anticipated to reach USD 18.4 billion by 2028, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 12.3% from 2021 to 2028. The factors driving market expansion is complex nature of Antibody Drug Conjugates (ADCs), increasing demand for manufacturing capacity as well as increasing number of research on antibody therapies. Around 70.0% of ADC projects are outsourced to contract development and manufacturing organisations. As ADCs are complex molecules, they require clean room biologic and high containment cytotoxic facilities for safe handling. Hence, there are real opportunities for